Amyotrophic lateral sclerosis (ALS) is frequently caused by mutations in the SOD1 gene. Here, we report the first SOD1 variant in Malta, an archipelago of three inhabited islands in southern Europe. We describe a patient with a sporadic form of ALS living on the island of Gozo in which the heterozygous SOD1 c.272A>C; p.(Asp91Ala) variant was detected. The patient had a late onset (79 years), sensory impairments and rapid disease progression culminating in respiratory failure. ALS has not yet developed in any of the three additional family members in which the D91A variant was identified. None of the healthy controls from the Maltese population were found to carry this variant. This report underscores the high prevalence of the D91A variant in Europe, despite the presence of a North-South gradient in its frequency, and confirms that this variant can be associated with dominant cases in Mediterranean countries.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259738 | PMC |
| http://dx.doi.org/10.1038/s41431-021-00975-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.
J Neurol
October 2024
Department of Neurology, Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany.
Article Synopsis
- Pathogenic variants in the SOD1 gene are found in about 2% of sporadic and 11% of familial ALS cases in Europe, with a focus on three main variants (R116G, D91A, L145F) in a study of 83 patients in Germany.
- Patients with the R116G variant experienced the most severe disease progression, with a median survival of just 22 months, significantly shorter than those with D91A (198 months) and L145F (87 months).
- All patients treated with tofersen showed reduced neurofilament light chain levels in their serum, indicating a potential treatment benefit, regardless of their specific SOD1 variant.
Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients.
Commun Med (Lond)
July 2024
Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Center for ALS and other Motor Neuron Disorders, Berlin, Germany.
Article Synopsis
- The introduction of the antisense oligonucleotide tofersen for treating ALS caused by SOD1 mutations emphasizes the need to clarify the impact of over 230 SOD1 variants, particularly the debated p.D91A variant common in Europe.
- A study involving 11 ALS patients treated with tofersen for up to 16 months shows that it significantly reduces serum neurofilament light chain (sNfL) levels, which are linked to ALS progression, in both homozygous and heterozygous SOD1 patients.
- These findings support the role of mono- and bi-allelic SOD1 variants as relevant targets for treatment, offering a new perspective for assessing causality based on biomarker responses in clinical
Frequency of and mutations in 302 sporadic ALS patients from three German ALS centers.
Amyotroph Lateral Scler Frontotemporal Degener
August 2023
Division of Neurodegenerative Disorders, Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences, Heidelberg University, Mannheim, Germany.
Article Synopsis
- * A study genotyped 302 SALS patients, revealing an 8.9% occurrence of hexanucleotide repeat expansions (HRE) and some mutations related to ALS.
- * The findings indicate a higher-than-expected frequency of HRE in SALS patients, suggesting that many may benefit from targeted gene therapies currently in development.
ALS in Finland: Major Genetic Variants and Clinical Characteristics of Patients With and Without the Hexanucleotide Repeat Expansion.
Neurol Genet
April 2022
Department of Neurology (H.L., K.K., P.J.T.), Helsinki University Hospital; Translational Immunology (H.L., L.J., K.K., P.J.T.), Research Programs Unit, University of Helsinki; Department of Psychology and Logopedics (J.L.), University of Helsinki, Finland; and Neuromuscular Diseases Research Section (B.J.T.), Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD.
Background And Objectives: To analyze the frequencies of major genetic variants and the clinical features in Finnish patients with amyotrophic lateral sclerosis (ALS) with or without the hexanucleotide repeat expansion.
Methods: A cohort of patients with motor neuron disease was recruited between 1993 and 2020 at the Helsinki University Hospital and 2 second-degree outpatient clinics in Helsinki. Finnish ancestry patients with ALS fulfilled the diagnosis according to the revised El Escorial criteria and the Awaji-criteria.
Individual Oligogenic Background in p.D91A- Amyotrophic Lateral Sclerosis Patients.
Genes (Basel)
November 2021
Medical Genetics Laboratory, Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
Article Synopsis
- * A study using Next Generation Sequencing analyzed both sporadic and familial ALS patients with p.D91A mutations, uncovering unique genetic variants, including some with unclear significance.
- * The findings indicate a complex genetic background in ALS cases with p.D91A mutations, suggesting that detailed genomic analysis could enhance diagnosis and inform targeted treatments in precision medicine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!